Catalyst Biosciences Strengthens Clinical Hemophilia Programs with Additions to its Senior Leadership Team
November 28 2017 - 8:30AM
-- Appoints Arwa Shurrab as Vice President of
Regulatory Affairs and Jamie Ellen Siegel, M.D., as Head of
Clinical Development --
Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage
biopharmaceutical company focused on developing novel medicines to
address hematology indications, today announced two key additions
to its clinical hemophilia programs with the appointments of Arwa
Shurrab as vice president of regulatory affairs and Jamie Ellen
Siegel, M.D., as the head of clinical development.
“The addition of Arwa Shurrab and Dr. Jamie
Siegel, with their extensive regulatory and clinical hematology
experience, significantly strengthens our hemophilia development
team,” said Nassim Usman, Ph.D., president and chief executive
officer of Catalyst. “We are confident that their contributions
will help us move forward in our clinical development program for
our subcutaneous, prophylactic FVIIa, marzeptacog alfa (activated),
and FIX, CB 2679d, candidates.”
Arwa Shurrab brings to Catalyst nearly 25 years
of regulatory affairs experience in the hematology field. She has
worked extensively leading regulatory and chemistry, manufacturing
and controls (CMC) activities. Before joining Catalyst, Arwa was
the director of regulatory affairs at Shire, where she served as a
director leading the Hematology CMC team in the development of
strategic plans and worldwide regulatory submissions. Prior to
Shire, she spent over 20 years at Baxter/Baxalta leading regulatory
activities for hemophilia products, including but not limited to
major BLA approvals and expansion to more than 70 countries.
Earlier in her career, Arwa held various positions in quality
control and quality assurance. Arwa holds a bachelor of science in
chemistry with a minor in biology from The American University in
Cairo.
Jamie Ellen Siegel, M.D., brings to Catalyst
over 30 years of clinical, clinical laboratory, and program
development experience in the hematology field, particularly in
hemophilia, with the last ten years in government and industry
settings. Jamie was director of the Hemophilia and Thrombosis
Center, Cardeza Foundation Special Hemostasis Laboratory, and
associate professor of medicine at Thomas Jefferson
University. She was co-director of the Medical Advisory Board
for the Hemophilia Federation of America and has received numerous
humanitarian awards from hemophilia patient advocacy groups. Before
joining Catalyst, Jamie held a number of high-level positions,
including medical director at Novo Nordisk and global clinical
leader at Bayer where she worked on two major hemophilia programs,
and was Chief, Thrombosis and Hemostasis branch at the National
Institutes of Health. She has overseen numerous clinical trials and
has authored over 35 hematology publications, including almost 20
peer-reviewed papers, seven peer-reviewed review articles, and
seven book chapters. Jamie received her medical degree from the
Medical College of Pennsylvania and holds a bachelor of arts from
Lehigh University.
About Catalyst Biosciences
Catalyst is a clinical-stage biopharmaceutical
company developing novel medicines to address hematology
indications. Catalyst is focused on the field of hemostasis,
including the subcutaneous prophylaxis of hemophilia and
facilitating surgery in individuals with hemophilia.
For more information, please visit www.catbio.com.
Forward-Looking Statements
This press release contains forward-looking
statements that involve substantial risks and uncertainties. All
statements included in this press release regarding our strategy,
the potential uses and benefits of CB 2679d and marzeptacog alfa
(activated) and development plans for these product candidates are
forward-looking statements. Actual results or events could differ
materially from the plans, intentions, expectations and projections
disclosed in the forward-looking statements. Various important
factors could cause actual results or events to differ materially
from the forward-looking statements that Catalyst makes, including,
but not limited to, the risk that clinical trials and studies may
be delayed and may not have satisfactory outcomes, that potential
adverse effects may arise from the testing or use of Catalyst’s
products, the risk that costs required to develop or manufacture
Catalyst’s products will be higher than anticipated, competition
and other factors that affect our ability to successfully develop
and commercialize our product candidates, and other risks described
in the “Risk Factors” section of the Company’s Annual Report on
Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC.
Catalyst does not assume any obligation to update any
forward-looking statements, except as required by law.
Contacts:
Investors:Fletcher Payne, CF Catalyst
Biosciences, Inc. 1.650.871.0761 investors@catbio.com
Media:Josephine Belluardo, Ph.D.LifeSci Public
Relations1.646.751.4361jo@lifescipublicrelations.com
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Sep 2024 to Oct 2024
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Oct 2023 to Oct 2024